• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Venture

LSP closes Health Economics Fund on €112m

  • Ellie Pullen
  • 12 March 2014
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Dutch healthcare investor Life Sciences Partners (LSP) has held the final close of its Health Economics Fund (HEF) on €112m, exceeding its €100m target.

The fund launched in February 2012 and simultaneously held its first close with a large cornerstone investment, meaning HEF could immediately begin seeking investments.

The fund made its first investment in US company Illuminoss Medical. HEF co-led the business's $28m series-C funding round in September 2012.

LSP Health Economics Fund

  • Closed on:

    €112m, Mar 2014

  • Focus:

    Medical devices, diagnostics, healthcare IT

  • Fund manager:

    Life Sciences Partners

The fund has a lifetime of 10 years with a five-year investment period. Terms and conditions for the vehicle are described as European standard by LSP HEF managing partner Rudy Dekeyser.

Investors
Prior to its first close, HEF received a €50m commitment from cornerstone investor Achmea, a Dutch healthcare insurance company. Another major investor in HEF is Dutch health insurer Menzis.

LSP began to target health insurance companies and family offices, the latter of which is described by Dekeyser as currently being very important to private equity, after interest from typical institutional investors, such as banks and pension funds, began to wane. Dekeyser said that the fundraising process began to accelerate quickly in the last three to four months, which allowed the fund to close above target.

The fund has also received commitments from French and German health insurers, as well as several large family offices and asset managers. Around €40m of the total amount was raised from family offices. The vehicle included a GP contribution.

The LPs for HEF were entirely from Europe, said Dekeyser, although the fund will invest in the US.

Investments
The fund will invest in European and US later-stage healthcare companies that have either commercialised their products or are very close to doing so.

HEF is different from LSP's other funds in that it will not invest in drug developing companies. It will focus its investments on companies that develop medical devices, diagnostics or healthcare-related IT solutions.

Around two thirds of the fund will be invested in European companies, with the balance going to US businesses. An investment in a European company is expected to be announced by LSP in the next couple of months.

People
Rudy Dekeyser is the managing partner for LSP HEF.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Venture
  • Benelux
  • Healthcare
  • Life Science Partners
  • Netherlands

More on Venture

Bettina Curtze of Redalpine
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
Andris K. Berzins of Change Ventures
Change Ventures aims to hold final close for EUR 20m third fund by mid-2024

Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds

  • Funds
  • 31 August 2023
Fund launches in euros
Iron Wolf Capital targets EUR 70m for second vehicle

Baltic investor anticipates early 2024 launch and will focus on early-stage AI and deeptech startups

  • Funds
  • 30 August 2023
Lauri Isotamm of Siena
Siena aims to hold new VC secondaries fund first close in late 2023 or early 2024

Secondary investments specialist will target EUR 30m to EUR 50m for new fund

  • Funds
  • 29 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013